IL2 and acute myeloid leukemia: The results support the essential role of IL-2 supplementation in the sustained expression of NKp30 on activated NK cells; NKp30 is a critical activating receptor in triggering the NK cell-mediated killing of diverse tumor cells and a prognostic biomarker in tumors including AML.